Evaluation of propoxyphene napsylate compound in post partum uterine cramping.
D000284:Administration, Oral / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002110:Caffeine / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D011431:Dextropropoxyphene / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009120:Muscle Cramp / Q000188:drug therapy*; D009282:Naphthalenesulfonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010615:Phenacetin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011644:Puerperal Disorders / Q000188:drug therapy*; D013997:Time Factors; D014591:Uterine Diseases / Q000188:drug therapy*
D009282:Naphthalenesulfonates; D002110:Caffeine; D010615:Phenacetin; D001241:Aspirin; D011431:Dextropropoxyphene